Koyfin Home > Directory > Health Care > Revance Therapeutics > Long-Term Debt

Revance Therapeutics Long-Term Debt Chart (RVNC)

Revance Therapeutics annual/quarterly Long-Term Debt from 2012 to 2020.
  • Revance Therapeutics Long-Term Debt for the quarter ending June 06, 2020 was $174m a 98.93% increase of 172m year over year
  • Revance Therapeutics Long-Term Debt for the last 12 months ending June 06, 2020 was $174m a 98.93% increase of 172m year over year
  • Revance Therapeutics Annual Long-Term Debt for 2016 was $2m a -185.58% decrease of -3m from 2015
  • Revance Therapeutics Annual Long-Term Debt for 2015 was $5m a 88.81% increase of 5m from 2014
  • Revance Therapeutics Annual Long-Term Debt for 2014 was $1m a -340.13% decrease of -2m from 2013
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Long-Term Debt Data

06/2020$174m
03/2020$171m
03/2017$1m
12/2016$2m
09/2016$3m
06/2016$4m
03/2016$4m
12/2015$5m
09/2015$6m
06/2015$7m

Annual RVNC Long-Term Debt Data

2016$2m
2015$5m
2014$1m
2013$3m
2012$11m
2011$63m